- Home
- MFM vs LXRX Comparison
MFM vs LXRX Comparison
Compare MFM & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFM
- LXRX
- Stock Information
- Founded
- MFM 1986
- LXRX 1995
- Country
- MFM United States
- LXRX United States
- Employees
- MFM N/A
- LXRX N/A
- Industry
- MFM Finance Companies
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- MFM Finance
- LXRX Health Care
- Exchange
- MFM Nasdaq
- LXRX Nasdaq
- Market Cap
- MFM 209.6M
- LXRX 228.8M
- IPO Year
- MFM N/A
- LXRX 2000
- Fundamental
- Price
- MFM $5.14
- LXRX $0.91
- Analyst Decision
- MFM
- LXRX Buy
- Analyst Count
- MFM 0
- LXRX 4
- Target Price
- MFM N/A
- LXRX $3.67
- AVG Volume (30 Days)
- MFM 108.1K
- LXRX 3.6M
- Earning Date
- MFM 01-01-0001
- LXRX 07-31-2025
- Dividend Yield
- MFM 4.08%
- LXRX N/A
- EPS Growth
- MFM N/A
- LXRX N/A
- EPS
- MFM 0.03
- LXRX N/A
- Revenue
- MFM N/A
- LXRX $31,213,000.00
- Revenue This Year
- MFM N/A
- LXRX N/A
- Revenue Next Year
- MFM N/A
- LXRX N/A
- P/E Ratio
- MFM $176.67
- LXRX N/A
- Revenue Growth
- MFM N/A
- LXRX 1251.21
- 52 Week Low
- MFM $4.37
- LXRX $0.28
- 52 Week High
- MFM $5.48
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- MFM 52.26
- LXRX 62.21
- Support Level
- MFM $5.12
- LXRX $0.64
- Resistance Level
- MFM $5.19
- LXRX $0.77
- Average True Range (ATR)
- MFM 0.04
- LXRX 0.06
- MACD
- MFM 0.01
- LXRX 0.00
- Stochastic Oscillator
- MFM 70.00
- LXRX 87.69
About MFM MFS Municipal Income Trust
MFS Municipal Income Trust is a diversified closed-end management investment company. Its investment objective is to seek high current income exempt from federal income tax, but may also consider capital appreciation. The fund invests a majority of its net assets, including assets attributable to preferred shares and borrowings for investment purposes, in municipal bonds.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.